Strs Ohio Sells 35,193 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Strs Ohio cut its IQVIA stake by 23.3% in Q4, selling 35,193 shares and now holds 115,846 shares (about 0.07% of the company) worth roughly $26.11 million; institutional investors own 89.62% of the stock.
• IQVIA beat Q4 expectations with $3.42 EPS vs. $3.40 and $4.36B revenue vs. $4.24B, set FY2026 EPS guidance of 12.550–12.850, and carries a consensus Buy rating with an average analyst target of $226.63.

Strs Ohio lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 23.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,846 shares of the medical research company's stock after selling 35,193 shares during the period. Strs Ohio owned 0.07% of IQVIA worth $26,113,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its holdings in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock valued at $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA in the 3rd quarter valued at about $30,000. Finally, Activest Wealth Management lifted its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $157.73 on Friday. The firm has a market cap of $26.77 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.57 and a beta of 1.18. The firm's 50 day simple moving average is $169.36 and its 200-day simple moving average is $201.55. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $220.00 and set a "buy" rating for the company in a report on Friday, February 6th. TD Cowen raised shares of IQVIA from a "hold" rating to a "buy" rating and increased their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $255.00 to $225.00 and set an "overweight" rating for the company in a report on Friday, February 6th. Wall Street Zen raised shares of IQVIA from a "hold" rating to a "buy" rating in a report on Sunday, April 19th. Finally, Jefferies Financial Group reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of "Buy" and an average target price of $226.63.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.